Article Sidebar

Submitted
11 November 2024
Accepted
10 December 2024
Published
11 December 2024
Download
PDF
Statistic
Read Counter : 3 Download : 1

Main Article Content

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that symmetrically damages the synovial membrane, affecting approximately thirteen percent of the global population. Systemic complications and substantial declines in quality of life may ensue from untreated RA. This study investigates the safety and efficacy of moxibustion and ozoralizumab in reducing disease activity scores in RA patients. Between July and November 2023, we performed an extensive search across four online databases (PubMed, Cochrane, Scopus, and ProQuest) utilizing keywords, reference searches, and other methodologies in alignment with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The obtained randomized controlled trials (RCTs) have been assessed using the Cochrane Risk of Bias 2 Risk of Bias Tools (ROB2). MetaInsight version 5.2.1 was employed to conduct this indirect network meta-analysis, which employed mean difference (MD) as summary statistics. This study demonstrated that ozoralizumab had a more significant effect on rheumatoid arthritis than placebo, as measured by DAS28 (MD=-1.88; 95% CI -2.24-(-1.52)) and moxibustion (MD=-0.69; 95% CI=-1.07-0.31). Ozoralizumab exhibited mild, moderate, and severe side effects, whereas moxibustion exhibited modest side effects compared to the placebo. In summary, ozoralizumab and moxibustion decreased DAS28 scores in rheumatoid arthritis patients, with ozoralizumab being the more effective treatment. Nevertheless, the adverse effects of ozoralizumab were more diverse than those of moxibustion.

Keywords

Ozoralizumab Moxibustion Rheumatoid Arthritis DAS28 Medicine

Article Details

License

Copyright (c) 2024 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Susanti, L. R., Mustika, A., Rahmawati, L. D., & Wungu, C. D. K. (2024). Efficacy and Safety of Ozoralizumab versus Moxibustion for Rheumatoid Arthritis. Folia Medica Indonesiana, 60(4), 358–371. https://doi.org/10.20473/fmi.v60i4.64949
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Alivernini, S., Tolusso, B., Petricca, L., et al (2019). Rheumatoid Arthritis, in: Mosaic of Autoimmunity. Elsevier, pp. 501–526. https://doi.org/10.1016/B978-0-12-814307-0.00046-3
  2. Deng, H., Shen, X., 2013. The Mechanism of Moxibustion: Ancient Theory and Modern Research. Evid. Based Complement. Alternat. Med. 2013, 1–7. https://doi.org/10.1155/2013/379291
  3. Gong, Y., Yu, Z., Wang, Y., et al (2019). Effect of Moxibustion on HIF-1 α and VEGF Levels in Patients with Rheumatoid Arthritis. Pain Res. Manag. 2019, 1–9. https://doi.org/10.1155/2019/4705247
  4. Hidayat, R., Suryana, B.P.P., Wijaya, et al (2021). Diagnosis dan Pengelolaan Artritis Reumatoid, Rekomendasi Perhimpunan Reumatologi Indonesia 2021. ed. Perhimpunan Reumatologi Indonesia.
  5. Higgins, J., Thomas, J., Chandler, J., et al (2022). Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Cochrane. www.training.cochrane.org/handbook
  6. Kerschbaumer, A., Sepriano, A., Smolen, J.S., et al (2020). Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis. 79, 744–759. https://doi.org/10.1136/annrheumdis-2019-216656
  7. Kiefer, C., Sturtz, S., Bender, R., (2015). Indirect Comparisons and Network Meta-Analyses. Dtsch. Ärztebl. Int. https://doi.org/10.3238/arztebl.2015.0803
  8. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan, n.d. Laporan Nasional Riskesdas 2018 - Repositori Badan Kebijakan Pembangunan Kesehatan [WWW Document]. URL https://repository.badankebijakan.kemkes.go.id/id/eprint/3514
  9. Liao, C., Tao, S., Xiong, Y., et al (2023). The Effects and Potential Mechanisms of Moxibustion for Rheumatoid Arthritis-Related Pain: A Randomized, Controlled Trial. J. Pain Res. Volume 16, 1739–1749. https://doi.org/10.2147/JPR.S408814
  10. Nasir, N., Majid, H., Khan, A., et al (2022). Disease activity correlates and functionality in patients with rheumatoid arthritis – real-world experience from a South Asian country. Rheumatology, 60(3), 183–191. https://doi.org/10.5114/reum.2022.117838
  11. Page, M.J., McKenzie, J.E., Bossuyt, P.M., et al (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https://doi.org/10.1136/bmj.n71
  12. Patidar, V., Shah, S., Kumar, R., et al (2022). A molecular insight of inflammatory cascades in rheumatoid arthritis and anti-arthritic potential of phytoconstituents. Mol. Biol. Rep. 49, 2375–2391. https://doi.org/10.1007/s11033-021-06986-7
  13. Pisaniello, H.L., Whittle, S.L., Lester, S., et al (2022). Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. BMC Rheumatol. 6, 67. https://doi.org/10.1186/s41927-022-00299-3
  14. Savitri, S. A., Kartidjo, P., Rahmadi, A. R., & Vikasari, S. N. (2019). Hubungan Pemilihan Obat dan Keberhasilan Terapi Pasien Rheumatoid Arthritis. Indonesian Journal of Clinical Pharmacy, 8(4), 237. https://doi.org/10.15416/ijcp.2019.8.4.237
  15. Shen, B., Sun, Q., Chen, H., Li, Y., Du, X., Li, H., & Xu, G. (2019). Effects of moxibustion on pain behaviors in patients with rheumatoid arthritis: A meta-analysis. Medicine, 98(30), e16413. https://doi.org/10.1097/MD.0000000000016413
  16. Takeuchi, T., 2023. Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor. Mod. Rheumatol. road038. https://doi.org/10.1093/mr/road038
  17. Takeuchi, T., Kawanishi, M., Nakanishi, et al (2022). Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 74, 1776–1785. https://doi.org/10.1002/art.42273
  18. Tanaka, Y., Kawanishi, M., Nakanishi, M., et al (2022). Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial). Mod. Rheumatol. roac119. https://doi.org/10.1093/mr/roac119
  19. Tao, S., Wang, X., Liao, C., et al (2021). The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients with Rheumatoid Arthritis. Pain Res. Manag. 2021, 1–10. https://doi.org/10.1155/2021/7466313
  20. Tipsing, W., Sawanyawisuth, K., (2021). Predictive clinical factors in rheumatoid arthritis using disease activity and functional score. Rheumatology 59, 309–312. https://doi.org/10.5114/reum.2021.110611
  21. Volkov, M., Schie, K. A., & Woude, D. (2020). Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunological Reviews, 294(1), 148–163. https://doi.org/10.1111/imr.12829
  22. Wells, G., Becker, J.-C., Teng, J., et al (2009). Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68, 954–960. https://doi.org/10.1136/ard.2007.084459
  23. World Health Organization: WHO, (2022). Musculoskeletal health [WWW Document]. URL https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions
  24. Yu, Z., Wang, Y., Li, Y., et al (2020). Effect of Moxibustion on the Serum Levels of MMP-1, MMP-3, and VEGF in Patients with Rheumatoid Arthritis. Evid. Based Complement. Alternat. Med. 2020, 1–9. https://doi.org/10.1155/2020/7150605
  25. Zhong, Y., Cheng, B.-, Zhang, L., et al (2020). Effect of Moxibustion on Inflammatory Cytokines in Animals with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Evid. Based Complement. Alternat. Med. 2020, 1–12. https://doi.org/10.1155/2020/6108619

Most read articles by the same author(s)